Eisai Inc. announced today that BELVIQ (pronounced BEL-VEEK) will be available to eligible patients by prescription in the United States beginning June 11.
BELVIQ was approved by the U.S. Food and Drug Administration on June 27, 2012 to be used along with a reduced-calorie diet and increased physical activity for chronic weight management in adults who have a body mass index (BMI) of 30 kg/m² or greater (obese), or BMI of 27 kg/m² or greater (overweight) with at least one weight-related medical condition such as high blood pressure, high cholesterol, or type 2 diabetes. It is not known if BELVIQ is safe and effective when taken with other prescription, over-the-counter, or herbal weight loss products, nor is it known if BELVIQ changes your risk of heart problems or stroke, or of death due to heart problems or stroke.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/60316-eisai-belviq-civ-chronic-weight-management-tablets-for-overweight-adults
Inspired by its surrounding southwestern landscape, the Health Sciences Education Building (HSEB) at The University of Arizona College of Medicine-Phoenix is one of the most innovative construction projects in the United States utilizing predominately recycled copper. Using nearly 6,000 copper panels and more than 10,000 copper parts, this 268,000 square-foot building consists of six stories of administration and faculty offices, lecture halls, learning studios, flexible classrooms, clinical suites, gross anatomy facilities, laboratories and conference rooms.
To view Multimedia News Release, go to http://www.multivu.com/mnr/61608-copper-development-green-sustainability-video-case-study-credit-architects
Diabetes experts met and determined that some self-monitoring blood glucose (SMBG) systems, despite meeting accuracy standards at the time of U.S. Food and Drug Administration (FDA) clearance, fail to consistently meet accuracy standards once on the market, potentially putting patient health at risk. In a public meeting convened by the Diabetes Technology Society on May 21, 2013, in Arlington, Virginia, leading academic clinicians, clinical chemists, medical device experts, patient advocates and FDA representatives reviewed a growing body of peer-reviewed research demonstrating that the performance of some blood glucose monitors on the market may not be meeting accuracy standards.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/61870-diabetes-technology-society-inaccurate-blood-glucose-monitors-risky
In a revolutionary treatment for early-onset scoliosis (EOS), a team of surgeons implanted adjustable growing rods in two children from California. The pioneering surgeries — the first ever in the United States — were performed on May 7th at Rady Children’s Hospital in San Diego. The Food and Drug Administration (FDA) granted Compassionate Use approval to use the MAGEC™ (MAGnetic Expansion Control) System, developed by Ellipse Technologies, Inc., for these two patients.
To view Multimedia News Release, go to http://www.multivu.com/mnr/61604-rady-children-s-hospital-san-diego-ellipse-magec-early-onset-scoliosis-eos
In recognition of Melanoma Monday® and National Melanoma/Skin Cancer Detection & Prevention MonthTM, MELA Sciences, Inc. (NASDAQ: MELA) visited the NASDAQ MarketSite in Times Square today to ring the Opening Bell and sponsor free skin cancer checks.
One American dies every hour from melanoma, the most deadly skin cancer. MELA Sciences, Inc. is the pioneer company behind MelaFind®, the first and only FDA-approved diagnostic tool that helps dermatologists detect melanoma at its most curable stage. MelaFind® was approved by the U.S. Food & Drug Administration (FDA) in Fall 2011, and since then has strategically rolled out the technology to dermatology practices across the country.
To view Multimedia News Release, go to http://www.multivu.com/mnr/61584-mela-sciences-rings-opening-bell-awareness-melanoma-detection-prevention
Raptor Pharmaceutical Corp. (“Raptor” or the “Company”) (Nasdaq: RPTP), today announced that the U.S. Food and Drug Administration (FDA) has approved PROCYSBI™ (cysteamine bitartrate) delayed release capsules for the treatment of nephropathic cystinosis in adults and children 6 years and older. In a Phase 3 study, PROCYSBI showed consistent cystine depletion over the full 12-hour dosing period. Sustained levels of cysteamine have not historically been achieved in the majority of patients in this population. Studies have shown that sustained cystine depletion in patients may significantly delay disease progression, including kidney dysfunction, dialysis, kidney transplant, organ failure and premature death.
To view Multimedia News Release, go to http://www.multivu.com/mnr/61338-raptor-pharmaceutical-procysbi-fda-approval-nephropathic-cystinosis
Modern semitrailers for the most part do a good job of keeping passenger vehicles from sliding underneath them, greatly increasing the chances of surviving a crash into the back of a large truck, recent tests by the Insurance Institute for Highway Safety (IIHS) show. But in crashes involving only a small portion of the truck’s rear, most trailers fail to prevent potentially deadly underride.
Earlier research showed that the minimum strength and dimensions required for underride guards are inadequate, prompting the Institute to petition the National Highway Traffic Safety Administration (NHTSA) in 2011 for tougher standards. The Institute also asked the agency to consider applying the standards to other types of large trucks, such as dump trucks that aren’t required to have any underride guards.
ADP®, a leading provider of employee health care benefits administration and human capital management (HCM) services, today announced the findings of a new ADP Research Institutes (SM) study indicating that if 2012 health benefit participation rate patterns persist into next year, then a portion of newly eligible employees may opt to remain uninsured because they perceive the cost of insurance is too significant a percentage of their annual income.
To view Multimedia News Release, go to http://www.multivu.com/mnr/60557-adp-research-institute-study-employee-health-benefits-participation
ADP®, a leading provider of employee healthcare benefits administration services and human capital management (HCM) services, today announced the findings of an ADP Research InstituteSM study based on actual, real-world data for approximately one million employees and more than two million covered lives. The ADP 2012 Study of Large Employer Health Benefits found that part-time workers eligible for health care benefits at large companies in the United States elect coverage at a significantly lower rate than full-time employees.
To view Multimedia News Release, go to http://www.multivu.com/mnr/60219-adp-research-institute-2012-study-of-large-employer-health-benefits
Dune Medical Devices, Inc., announced today that its breakthrough intra-operative tissue assessment tool for early-stage breast cancer surgery, the MarginProbe System, has received Premarket Approval (PMA) by the United States Food and Drug Administration. The technology significantly improves surgeons’ ability to intra-operatively identify
More than 46 million turkeys will be cooked this Thanksgiving holiday, according to the National Turkey Federation. In an effort to help protect Americans from foodborne illness during the Thanksgiving season, the Ad Council, the U.S. Department of Agriculture (USDA)’s Food Safety and Inspection Service, the U.S. Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC), in partnership with Food Network Star’s Martie Duncan, are helping to dispel many of the common myths surrounding the preparation and serving of the holiday turkey meal.
To view Multimedia News Release, go to http://www.multivu.com/mnr/59193-ad-council-usda-hhs-food-safe-families-public-service-thanksgiving
To promote the adoption of teenagers from foster care, the Administration for Children and Families (ACF), AdoptUSKids and the Ad Council are unveiling a new series of multimedia public service advertisements (PSAs). Today, more than 33,000 teenagers await adoption from the U.S. foster care system. Nearly 50 percent (14,000) are between the ages of 14 and 16.
These new PSAs are part of the Adoption from Foster Care campaign launched in 2004. Since the launch of the campaign more than 15,000 children have been placed with a permanent family.
To view Multimedia News Release, go to http://www.multivu.com/mnr/58394-ad-council-adoption-psas-raise-awareness-of-teenagers-in-us-foster-care
